Robert Buckheit - Jul 27, 2021 Form 4 Insider Report for Cytocom, Inc. (STAB)

Role: Chief Technology Officer
Signature: /s/ Peter Aronstam, Attorney-in-fact for Robert W. Buckheit, Jr.
Stock symbol: STAB
Transactions as of: Jul 27, 2021
Transactions value $: $0
Form type: 4
Date filed: 7/29/2021, 09:34 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STAB	Common Stock, par value $0.005 per share	Award	$0	+24.4K		$0.00	24.4K	Jul 27, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares received pursuant to an Agreement and Plan of Merger ("merger agreement"), entered into by Cytocom Inc. ("Old Cytocom") and Cleveland BioLabs, Inc ("New Cytocom" or "Issuer"). Per the "merger agreement", each share of Old Cytocom (i) common stock, (ii) preferred stock that was not converted into Old Cytocom common stock immediately prior to the effective time of the Merger, and (iii) each vested restricted stock unit of Old Cytocom (excluding, in each case, dissenting shares and shares held in treasury) converted into the right to receive a number of shares of New Cytocom common stock based on an exchange formula set forth in the merger agreement (which we refer to as the "merger consideration").

Content

Shares received pursuant to an Agreement and Plan of Merger ("merger agreement"), entered into by Cytocom Inc. ("Old Cytocom") and Cleveland BioLabs, Inc ("New Cytocom" or "Issuer"). Per the "merger agreement", each share of Old Cytocom (i) common stock, (ii) preferred stock that was not converted into Old Cytocom common stock immediately prior to the effective time of the Merger, and (iii) each vested restricted stock unit of Old Cytocom (excluding, in each case, dissenting shares and shares held in treasury) converted into the right to receive a number of shares of New Cytocom common stock based on an exchange formula set forth in the merger agreement (which we refer to as the "merger consideration").